

Malignant Hematology Areas of Interest (Investigator Initiated Studies and Research Collaborations)

REGN1979 (CD20xCD3) odronextamab

Non-interventional proposals:

- Investigating tumor and immune correlates of response to CD20xCD3 bispecific antibodies in B-NHL

Interventional proposals:

- Novel treatment combinations, including combinations with novel agents targeting non-redundant pathways, in all lines of therapy for the treatment of b-NHL
- Sequencing Odronektamab in the treatment paradigm for the treatment of B-NHL
- Investigating Odronektamab in hard-to-treat, medically unaddressed, and rare populations with Lymphomas in high unmet medical needs
- Predictors of response and/or (primary or acquired) resistance to Odronektamab in the treatment of b-NHL

Note that Regeneron is not currently accepting proposals for Investigator Sponsored Studies or Research Collaborations using odronextamab in the European Union.

(v4.1 3Apr2023)

REGN5458 (BCMA x CD3 bispecific antibody)

Non-interventional proposals in Plasma Cell Dyscrasias exploring:

- Biomarkers leading to better characterization, management, and treatment options
 - BCMA expression pre- and post-treatment (standard of care agents or novel agents)
 - Early disease progression and/or mechanisms of resistance
 - T cell phenotyping in biopsy and aspirate
 - Plasma cell markers associated with progression/resistance to standard of care
 - Immune subset characterization including T cell suppressive mechanisms
 - Biomarkers for future therapeutic target development
 - Biomarkers of Plasma Cell Dyscrasias
- Models to assess functional immune responsiveness to BCMA x CD3
- Experimental models to explore novel combinations with BCMA x CD3

Interventional proposals:

- Studies to explore linvoseltamab as **monotherapy** in Multiple Myeloma in lines earlier than in Triple Class Refractory
 - Treatment sequencing strategies
 - Special patient (sub) populations based on patient demographics and disease characteristics
 - Alternative mitigation procedures to manage bispecific adverse events
 - Biomarker signatures in linvoseltamab-treated patients
- No linvoseltamab combination therapy proposals will be considered at this time.

Note that Regeneron is not currently accepting proposals for Investigator Sponsored Studies or Research Collaborations using linvoseltamab in the European Union.

(v4.0, 3Apr2023)